Drug Panel 9, Urine - Screen with Reflex to Confirmation/Quantitation
Ordering Recommendation
Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out drug exposure. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Specimen Required
Random urine.
Transfer 8 mL urine with no additives or preservatives to ARUP Standard Transport Tubes. (Min: 4 mL)
Refrigerated.
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month
Methodology
Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
Reference Interval
Drugs Covered and Cutoff Concentrations |
|
---|---|
Drugs/Drug Classes |
Screen |
THC (Cannabinoids) | 50 ng/mL |
Cocaine | 150 ng/mL |
Opiates | 300 ng/mL |
Oxycodone | 100 ng/mL |
Phencyclidine | 25 ng/mL |
Amphetamines | 300 ng/mL |
MDMA (Ecstasy) | 500 ng/mL |
Barbiturates | 200 ng/mL |
Benzodiazepines | 200 ng/mL |
Methadone | 150 ng/mL |
Propoxyphene | 300 ng/mL |
Interpretive Data
The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
Oxycodone results are reported with the opiates results. MDMA results are reported with the amphetamines results. The following opioids are not detected in this test: fentanyl, buprenorphine, meperidine, tramadol, and tapentadol. A comprehensive panel that includes these opioids is available or individual opioid testing can be ordered. Refer to aruplab.com for test information.
For medical purposes only; not valid for forensic use.
FDA
Note
If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.
To order testing for individual opioids, refer to Fentanyl and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 0092570), Buprenorphine and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2010092), Meperidine and Metabolite Quantitative, Urine (ARUP test code 3000248), Tramadol and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2002736). For the comprehensive panel, refer to Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).
Hotline History
Hotline History
CPT Codes
80307; if reflexed, add 80325; 80345; 80346; 80349; 80353; 80358; 80359; 80361; 80365; 80367; 83992 (Reflexed Alt Code: G0480 )
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0090386 | Creatinine, Urine | 2161-8 |
0090399 | CDASU 9 Comments | 48767-8 |
0092191 | Amphetamines, Urn, Screen | 19261-7 |
0092192 | Cocaine, Urn, Screen | 19359-9 |
0092193 | Opiates, Urn, Screen | 19300-3 |
0092194 | Phencyclidine, Urn, Screen | 19659-2 |
0092195 | THC, Urn, Screen | 19292-2 |
0092196 | Barbiturates, Urn, Screen | 19270-8 |
0092197 | Benzodiazepines, Urn, Screen | 14316-4 |
0092198 | Propoxyphene, Urn, Screen | 19429-0 |
0092199 | Methadone, Urn, Screen | 19550-3 |
Aliases
- Amphetamines, Urine
- Barbiturates, Urine
- Benzodiazepines, Urine
- CDASU 9 Comments
- Cocaine, Urine
- Creatinine, Urine
- Marijuana, Urine
- Methadone, Urine
- Opiates, Urine
- Pain Management
- Phencyclidine, Urine
- Propoxyphene, Urine